We have previously shown that the simultaneous exposure of Hep-2 cells to
cucurbitacin B and
docetaxel significantly enhances anticancer activity of these cells by suppressing Stat3 activation and down-regulating the expression levels of key cell cycle and anti-apoptosis regulators. In order to determine whether
cucurbitacin B can also enhance the sensitivity of Hep-2 laryngeal cells to
cisplatin, we treated Hep-2 cells with either
cucurbitacin B,
cisplatin, or the combination and evaluated these cells for proliferation, cell cycle distribution, and apoptosis. Our results demonstrate that, in comparison to single agent
cucurbitacin B or
cisplatin treated cells, Hep-2 cells treated with a
cucurbitacin B/
cisplatin combination display synergistic effects on growth inhibition, cell cycle arrest, and apoptosis induction. Western blot analysis using
protein extracts from Hep-2 cells treated with
cucurbitacin B,
cisplatin, or the combination largely recapitulated the observations made when treated with the
cucurbitacin B/
docetaxel combination. More specifically, Hep-2 cell lines treated with the
cucurbitacin B/
cisplatin combination demonstrated a significantly reduced level of p-Stat3 in comparison with single agent treated cells. In addition,
cucurbitacin B/
cisplatin treated Hep-2 cells also demonstrated a significant reduction in Bcl-2 and
Cyclin B1 protein levels compared to single agent
cucurbitacin B or
cisplatin treated cells. Xenograft models containing Hep-2 cells in mice also demonstrated that this
cucurbitacin B/
cisplatin combination led to the synergistic inhibition of
tumor growth. Taken together, these results suggest that the
cucurbitacin B/
cisplatin combination treatment may be a potentially useful therapeutic option for individuals diagnosed with
laryngeal cancer.